Evidence map›Paper›PMID 34758991›Full record

ArticleBMJ open2021

Code status documentation at admission in COVID-19 patients: a descriptive cohort study.

Saskia Briedé, Harriet M R van Goor, Titus A P de Hond, Sonja E van Roeden, Judith M Staats, Jan Jelrik Oosterheert, Frederiek van den Bos, Karin A H Kaasjager

Abstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Saskia BriedéInternal Medicine and Dermatology, University Medical Centre Utrecht, Utrecht, The Netherlands s.briede-2@umcutrecht.nl.ORCID 0000-0002-4673-2667
Harriet M R van GoorInternal Medicine and Dermatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Titus A P de HondInternal Medicine and Dermatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Sonja E van RoedenInternal Medicine and Dermatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Judith M StaatsInternal Medicine and Dermatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Jan Jelrik OosterheertInternal Medicine and Dermatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Frederiek van den BosDepartment of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands.
Karin A H KaasjagerInternal Medicine and Dermatology, University Medical Centre Utrecht, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe COVID-19 pandemic pressurised healthcare with increased shortage of care. This resulted in an increase of awareness for code status documentation (ie, whether limitations to specific life-sustaining treatments are in place), both in the medical field and in public media. However, it is unknown whether the increased awareness changed the prevalence and content of code status documentation for COVID-19 patients. We aim to describe differences in code status documentation between infectious patients before the pandemic and COVID-19 patients.

settingUniversity Medical Centre of Utrecht, a tertiary care teaching academic hospital in the Netherlands.

participantsA total of 1715 patients were included, 129 in the COVID-19 cohort (a cohort of COVID-19 patients, admitted from March 2020 to June 2020) and 1586 in the pre-COVID-19 cohort (a cohort of patients with (suspected) infections admitted between September 2016 to September 2018). PRIMARY AND SECONDARY OUTCOME MEASURES: We described frequency of code status documentation, frequency of discussion of this code status with patient and/or family, and content of code status.

resultsFrequencies of code status documentation (69.8% vs 72.7%, respectively) and discussion (75.6% vs 73.3%, respectively) were similar in both cohorts. More patients in the COVID-19 cohort than in the before COVID-19 cohort had any treatment limitation as opposed to full code (40% vs 25%). Within the treatment limitations, 'no intensive care admission' (81% vs 51%) and 'no intubation' (69% vs 40%) were more frequently documented in the COVID-19 cohort. A smaller difference was seen in 'other limitation' (17% vs 9%), while 'no resuscitation' (96% vs 92%) was comparable between both periods.

conclusionWe observed no difference in the frequency of code status documentation or discussion in COVID-19 patients opposed to a pre-COVID-19 cohort. However, treatment limitations were more prevalent in patients with COVID-19, especially 'no intubation' and 'no intensive care admission'.

Indexed as

COVID-19Cohort StudiesDocumentationHumansPandemicsSARS-CoV-2adult intensive & critical careCOVID-19internal medicine

Identifiers

PMID34758991
PMCPMC8587534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.